Targeting Drug Resistance in Cancer: Dimethoxycurcumin as a Functional Antioxidant Targeting ABCC3
Antioxidants · 16.05.2025 · 14 (5) · 599
DOI: 10.3390/antiox14050599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 16.05.2025. Verfasst von Jochem Nelen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Structural Bioinformatics and High Performance Computing Research Group (BIO-HPC), HiTech Innovation Hub, UCAM Universidad Católica de Murcia, 30107 …. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cátedra Villapharma-UCAM. Powered@NLHPC, Cátedra Villapharma-UCAM, supercomputing infrastructure of the NLHPC.
Abstract (Originalsprache)
The development of new anticancer therapies remains challenging due to tumor heterogeneity and the frequent emergence of multidrug resistance (MDR). Natural products have garnered increasing attention as alternative or complementary therapeutic agents due to their bioactivity and reduced toxicity. Polyphenols, particularly curcumin and its derivatives, have shown promise in modulating signaling pathways, enhancing chemosensitivity, and overcoming drug resistance. The anticancer potential of dimethoxycurcumin, a chemically modified curcumin derivative identified through consensus fingerprint similarity screening, was investigated for its potential to inhibit ABCC3 (MRP3)—a member of the ATP-binding cassette (ABC) transporter family implicated in drug efflux, tumor cell survival, and resistance. In vitro experiments demonstrated that dimethoxycurcumin significantly reduced cancer cell viability and colony formation, indicating a strong inhibitory effect on ABCC3 function. These results suggest that dimethoxycurcumin may sensitize cancer cells to chemotherapy by targeting resistance pathways. The data presented contribute to the growing body of evidence suggesting that bioactive plant-derived compounds, including chemically modified derivatives, may hold therapeutic potential in oncology by modulating multidrug resistance pathways. Targeting ABC transporters with natural compound derivatives could offer a promising strategy for developing more effective and less toxic anticancer therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Structural Bioinformatics and High Performance Computing Research Group (BIO-HPC), HiTech Innovation Hub, UCAM Universidad Católica de Murcia, 30107 Murcia, Spain.
- Health Sciences PhD Program, Universidad Católica de Murcia UCAM, Campus de los Jerónimos n°135, Guadalupe, 30107 Murcia, Spain.
- University of Parma, Department of Medicine and Surgery, Via Volturno 39, 43125 Parma, Italy.
- Eurofins-Villapharma Research, 30320 Murcia, Spain.
ORCID-Profile: Jochem Nelen, Valeria Naponelli, Marco Falasca, Horacio Pérez-Sánchez
Förderung
- Cátedra Villapharma-UCAM. Powered@NLHPC
- Cátedra Villapharma-UCAM
- supercomputing infrastructure of the NLHPC
- Plataforma Andaluza de Bioinformática of the University of Málaga
Zitieren
APA
Nelen, J., Naponelli, V., Villalgordo-Soto, J. M., Falasca, M., & Pérez-Sánchez, H. (2025). Targeting Drug Resistance in Cancer: Dimethoxycurcumin as a Functional Antioxidant Targeting ABCC3. Antioxidants, 14(5), 599. https://doi.org/10.3390/antiox14050599
Vancouver
Nelen J, Naponelli V, Villalgordo-Soto JM, Falasca M, Pérez-Sánchez H. Targeting Drug Resistance in Cancer: Dimethoxycurcumin as a Functional Antioxidant Targeting ABCC3. Antioxidants. 2025;14(5):599. doi:10.3390/antiox14050599
BibTeX
@article{Nelen2025,
author = {Nelen, Jochem and Naponelli, Valeria and Villalgordo-Soto, José Manuel and Falasca, Marco and Pérez-Sánchez, Horacio},
title = {Targeting Drug Resistance in Cancer: Dimethoxycurcumin as a Functional Antioxidant Targeting ABCC3},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {5},
pages = {599},
doi = {10.3390/antiox14050599}
}
EUVIMED